This interview with a US-based key opinion leader (KOL) offers comprehensive insights into current disease landscape for patients with anemia in chronic kidney disease (CKD), and expectations regarding emerging pipeline therapies. The discussion covers the current treatment paradigm with emphasis on erythropoiesis-stimulating agents (ESAs) and iron, as well as perspectives on the hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor class, challenges to its adoption, and its prospective roles in future disease management.

This interview was conducted on 3 June 2025.